

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

Isabelle Demeestere^{a,b,*}, Samuel M. Niman^{c,d}, Ann H. Partridge^{e,f}, Daniela S. Diego^g, Roswitha Kammler^h, Monica Ruggeriⁱ, Marco Colleoni^j, Chikako Shimizu^k, Cristina Saura^{l,m}, Karen A. Gelmonⁿ, Anna B. Saetersdal^o, Judith R. Kroep^{p,q}, Audrey Mailliez^r, Frederic Amant^{s,t,u}, Manuel Ruiz-Borrego^{v,w}, Jeong Eon Lee^{x,y}, Akemi Kataoka^z, Janice M. Walshe^{aa,ab}, Junko Takei^{ac}, Simona Borstnar^{ad}, Virginia F. Borges^{ae}, Christobel Saunders^{af,ag}, Snezana Susnjar^{ah}, Vesna Bjelic-Radisic^{ai,aj}, Fatima Cardoso^{ak}, Jane Lowe Meisel^{al}, Jennifer F. Kawwass^g, Tanja Spanic^{am}, Sarra El-Abed^{an}, Martine Piccart^{an,ao}, Larissa A. Korde^{ap}, Aron Goldhirsch^{aq,ar,1}, Richard D. Gelber^{c,d,as,at}, Olivia Pagani^{au,av,aw}, Hatem A. Azim Jr.^{ax}, Fedro A. Peccatori^{ay}, for the International Breast Cancer Study Group and the POSITIVE Trial Collaborators

^a Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium

^b Gynecology and Obstetrics Department, Fertility Clinic, H.U.B Erasme Hospital, Brussels, Belgium

^c International Breast Cancer Study Group Statistical Center, Boston, MA, USA

^d Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA

^e Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

^f Harvard Medical School, Boston, MA, USA

^g Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA

^h Translational Research Coordination, International Breast Cancer Study Group, a Division of ETOP IBCSG Partners Foundation, Bern, Switzerland

ⁱ Program for Young Patients, International Breast Cancer Study Group, a Division of ETOP IBCSG Partners Foundation, Bern, Switzerland

^j Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy

^k Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan

^l Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain

^m SOLTI Breast Cancer Research Group, Barcelona, Spain

ⁿ BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC, Canada

^o Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway

^p Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands

^q Dutch Breast Cancer Research Group (BOOG), the Netherlands

^r Department of Medical Oncology, Breast Cancer Unit, Centre Oscar Lambret, Lille, France

^s Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium

^t Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium

^u Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, the Netherlands

^v GEICAM Spanish Breast Cancer Group, Madrid, Spain

^w Hospital Virgen Del Rocio Sevilla, Sevilla, Spain

^x Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

^y Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea

^z Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan

^{aa} Cancer Trials Ireland, Dublin, Ireland

^{ab} Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland

^{ac} St Luke's International Hospital, Breast Center, Tokyo, Japan

^{ad} Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia

^{ae} Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA

^{af} Department of Surgery, University of Melbourne, Melbourne, VIC, Australia

^{ag} Royal Melbourne Hospital, Melbourne, VIC, Australia

* Corresponding author. Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium.

E-mail address: Isabelle.demeestere@ulb.be (I. Demeestere).

<https://doi.org/10.1016/j.breast.2025.104547>

Received 18 May 2025; Received in revised form 11 July 2025; Accepted 23 July 2025

Available online 26 July 2025

0960-9776/© 2025 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

^{ah} Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

^{ai} Breast Unit, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany

^{aj} Austrian Breast and Colorectal Study Group (ABCSCG), Austria

^{ak} Breast Unit, Champalimaud Foundation and Advanced Breast Cancer (ABC) Global Alliance, Lisbon, Portugal

^{al} Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA

^{am} Europa Donna, Ljubljana, Slovenia and Europa Donna – The European Breast Cancer Coalition, Milan, Italy

^{an} Breast International Group, Brussels, Belgium

^{ao} Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium

^{ap} Breast and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA

^{aq} International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland

^{ar} IEO, European Institute of Oncology, IRCCS, Milan, Italy

^{as} Frontier Science Foundation, Boston, MA, USA

^{at} Harvard TH Chan School of Public Health, Boston, MA, USA

^{au} Geneva University Hospitals, Geneva, Switzerland

^{av} Lugano University, Lugano, Switzerland

^{aw} Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

^{ax} Cairo Cure Oncology Center, Cairo, Egypt

^{ay} Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy

ARTICLE INFO

Keywords:

Breast cancer

Pregnancy

Assisted reproductive technology

Ovarian reserve

Premature ovarian insufficiency

ABSTRACT

Purpose: The POSITIVE trial showed that premenopausal women with breast cancer (BC) can safely pause adjuvant endocrine treatment (ET) to attempt conception. 74 % of patients conceived spontaneously or through assisted reproductive technology (ART); Investigating hormonal factors that predict fertility was a key secondary endpoint.

Methods: Hormonal factors were assessed in non-pregnant women at months 3, 6, and 12 after ET interruption. The frequency of low ovarian reserve, defined as anti-Mullerian hormone (AMH) < 0.5 ng/mL at month 3, and of premature ovarian insufficiency (POI), defined as follicle stimulating hormone (FSH) > 25 IU/L at month 12, were primary measures. Secondary analyses to predict pregnancy included AMH, FSH, thyroid stimulating hormone (TSH), prolactin and ovulatory status (defined as progesterone >3 ng/mL at month 6), considering covariates such as age, treatment, and ART use.

Results: Of 518 women enrolled in POSITIVE, 438 were eligible for low ovarian reserve analysis. Low ovarian reserve was observed in 209 women (47.7 %), more frequently among older women and those with prior chemotherapy, but not in relation to ET type or duration. Overall, low ovarian reserve was associated with reduced odds of pregnancy (OR:0.52; 95 % CI:0.31–0.87). Of 142 patients evaluated for POI, 16.7 % of those who received prior chemotherapy experienced POI. FSH at month 3 was associated with POI, but only modestly with spontaneous pregnancy (OR:0.96; 95 % CI: 0.93–1.00); other factors were not predictive of pregnancy.

Conclusion: Hormonal factors are associated with pregnancy in BC patients pausing adjuvant ET to conceive, and their assessment may help to optimize fertility counseling.

Trial registration: [ClinicalTrials.gov](https://clinicaltrials.gov) number NCT02308085.

1. Introduction

Breast cancer (BC) is the most frequent cancer diagnosed in women of reproductive age [1,2]. While prognosis continues to improve, the potential detrimental effects of (neo)adjuvant systemic therapy on fertility may significantly impact treatment decisions, adherence, and future quality of life [3]. Patients with hormone receptor-positive (HR+) BC have traditionally been advised to delay childbearing until completing 5–10 years of adjuvant endocrine therapy (ET), which contributes to reduced fertility due to advancing age [4,5]. Recent findings from the POSITIVE trial, demonstrating no increase in short-term risk of BC recurrence in patients who interrupted ET for pregnancy, will likely lead to an increasing number of patients choosing to temporarily pause treatment to conceive [6]. While most patients became pregnant on POSITIVE, questions remain regarding predictive factors for pregnancy in this population, given the study allowed for natural pregnancy or the use of Assisted Reproductive Technology (ART) [7].

Historically menstruation has served as a surrogate indicator of ovarian function recovery in young BC survivors following treatment [8]. However, even in the presence of continued menstrual cycles, gonadotoxic cancer treatment can lead to a premature depletion of primordial follicles, resulting in a reduced ovarian reserve and, ultimately, premature ovarian insufficiency (POI) - defined as the loss of

ovarian function and ability to conceive before the age of 40 [9,10]. The risk of POI makes fertility preservation prior to cancer treatment critically important [10].

The anti-Mullerian Hormone (AMH) level has been recognized as the most accurate marker of ovarian reserve [11]. AMH levels are strong predictors of the number of mature oocytes retrieved during ovarian stimulation cycles [12], however, they do not predict the likelihood of achieving spontaneous pregnancy [13,14]. It has been shown to significantly decrease in BC patients during chemotherapy, with a potential for partial recovery within the first year of follow-up [15–17]. The impact of post-treatment ovarian reserve depletion on the ability to conceive and the risk of POI remain inadequately explored in this population [14]. Further research is needed to evaluate the reliability of post-treatment hormone profile and other potential predictive factors of pregnancy for improving fertility counseling.

Here, we evaluated the hormone profile of the POSITIVE trial cohort to identify hormonal factors after ET interruption predictive of subsequent pregnancy.

2. Patients and methods

2.1. Population

Hormone assessment was a predefined secondary endpoint of the POSITIVE trial, a prospective, international, multicenter, single-arm trial conducted across 20 countries. The study design, patient

¹ Deceased.

characteristics, and primary results were previously described [6,18]. In brief, a total of 518 premenopausal patients aged ≤ 42 years with stage I to III HR + BC who received adjuvant ET for ≥ 18 but ≤ 30 months were enrolled in the trial from December 2014 to December 2019. Patients were recommended to interrupt ET for a maximum of 2 years to attempt pregnancy after a 3-month ET washout period.

The chemotherapy regimens were previously described in the cohort of patients included in the POSITIVE trial. The majority of patients (67.2 %) who received chemotherapy were treated with a combination of anthracycline and taxane therapy. Additionally, 20.6 % received taxane-based therapy while the remaining patients received either anthracycline alone or other chemotherapy regimens [6].

Information on resumption of menstrual cycles and method of conception as well as pregnancy and disease outcomes were previously reported [6,7].

The study was sponsored by the IBCSG in accordance with the International Council for Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki, and local clinical research regulations. All patients gave written informed consent. The IBCSG was responsible for trial design, data collection and management, blood sample centralization, and statistical analysis. Participating centers were affiliated with cooperative groups of the Breast International Group and the United States National Clinical Trials Network.

2.2. Study objectives

This analysis aims to evaluate the risk of low ovarian reserve and POI in POSITIVE trial participants after ET interruption, and to characterize the association of AMH and FSH levels with the likelihood of pregnancy, also considering covariates such as age, adjuvant therapy (ET \pm chemotherapy), and use of ART which we previously investigated [7]. Other factors evaluated include thyroid function, prolactin (PRL) and ovulatory status.

2.3. Hormonal assays and definitions

Hormone assessment for patients who were not pregnant included, 3-month post-ET interruption, ovarian reserve (AMH), ovarian function (follicle stimulating hormone -FSH and estradiol -E2), and ovulatory status (progesterone) (Fig. 1). Low ovarian reserve was defined as AMH

values < 0.5 ng/ml at month 3 (or at month 12 if AMH at month 3 was not available) [8,15,16]. Ovarian function was evaluated using FSH during the early follicular phase (day 2–5 of the menstrual cycle) at month 3 and at month 12 in non-pregnant women. POI was defined as FSH > 25 IU/L at month 12 during early follicular phase in non-pregnant women [19]. If amenorrhea, samples were collected at any time. Ovulatory status was defined as progesterone levels > 3 ng/ml in the luteal phase (days 21–25 of the menstrual cycle) at month 6 [20].

FSH, E2, progesterone and AMH were centrally measured as described in the Supplementary Material – Populations and Methods.

Thyroid stimulating hormone (TSH) and PRL levels were assessed locally at month 3 and recorded as ‘Normal’ or ‘High’ for PRL, and ‘Normal’, ‘Low’, or ‘High’ for TSH. If abnormal, PRL and TSH measurements were repeated at month 12.

2.4. Transvaginal Ultrasound

Transvaginal Ultrasound was performed at month 3 to assess, optionally, antral follicular count (AFC).

2.5. Statistical methods

The secondary endpoint population consisted of 497 out of the 518 patients enrolled in the POSITIVE trial [6]. Fig. 2 shows the flow diagram of patients in the different analysis populations, further defined in the Supplementary Material – Populations and Methods and Supplementary Table 1.

All AMH samples in non-pregnant women were considered for analysis irrespective of the days of the cycle considering that AMH is stable during the menstrual cycle [21]. Classification of low ovarian reserve (Yes/No) was based on serum AMH samples taken at month 3, or if unavailable, at month 12. Classification of POI (Yes/no) was based on FSH samples taken at months 12. The distribution of FSH and E2 at month 3 post-ET washout was also examined. All FSH and E2 samples taken during pregnancy or outside the menstrual cycle days 2–5 were excluded from analysis, except if the last menstruation occurred > 35 days before blood collection as indicative of amenorrhea.

Oligomenorrhea was defined as 120 consecutive days without menstruation and without pregnancy prior to the month 12 sample date.

Categorical data was described as frequency and percent, overall,




Fig. 1. Serum collection for hormone assessments and transvaginal ultrasound (US) for endometrium thickness and antral follicular count (AFC) evaluation in the POSITIVE trial.




Fig. 2. Flow Chart of the study populations.

and by subgroups as appropriate. Continuous data was summarized as median and interquartile range (IQR) in the manuscript, with full distributions (mean, median, min, max, 25th percentile, and 75th percentile) provided in supplementary tables, overall, and by subgroups as appropriate. Association of factors with binary endpoints such as pregnancy (yes/no) and low ovarian reserve (yes/no) were evaluated using multivariable logistic regression. Multivariable linear regression and correlation estimates were utilized when an outcome was continuous. Details on statistical methods implemented are in the Supplementary Material – Populations and Methods.

3. Results

3.1. Assessment of ovarian reserve

Of 497 women in the secondary analysis population, 438 had useable AMH measurements (Fig. 2), 209 (47.7 %) had low ovarian reserve, defined as AMH <0.5 ng/ml at month 3, or month 12 (Table 1). In a multivariable logistic regression model, younger age (<35 vs. 35–39 or 40–42 years) and no prior chemotherapy (vs. prior chemotherapy) were associated with lower odds of low ovarian reserve (Suppl Table 2). Importantly, neither the type nor the duration of ET were associated with low ovarian reserve.

3.2. Premature ovarian insufficiency (POI)

Of 497 women in the secondary analysis population, 142 patients who were not pregnant at month 12 were eligible for POI analysis, all of whom were also eligible for low ovarian reserve analysis. The median

Table 1

Patient and treatment characteristics according to Low Ovarian Reserve status and according to 12-month Premature Ovarian Insufficiency (POI) status.

	Low ovarian reserve		POI	
	Patients	Number (%) with LOR	Patients	Number (%) with POI
Patients Included in Analysis	438	209 (47.7)	142	15 (10.6)
Age at enrollment (years)				
<35	142	50 (35.2)	40	1 (2.5)
35–39	192	96 (50.0)	58	7 (12.1)
40–42	104	63 (60.6)	44	7 (15.9)
Prior chemotherapy				
No	165	38 (23.0)	52	0 (0.0)
Yes	273	171 (62.6)	90	15 (16.7)
Prior Endocrine Therapy				
OFS±AI	72	34 (47.2)	26	4 (15.4)
SERM only	174	78 (44.8)	47	5 (10.6)
Other	192	97 (50.5)	69	6 (8.7)

OFS= Ovarian Function Suppression, AI= Aromatase Inhibitors; SERM= Selective estrogen receptor modulator.

* Low ovarian reserve is defined as AMH<0.5 ng/ml at month 3, or, if month 3 AMH was not available, AMH<0.5 ng/ml at month 12. Analysis was based on 3-month AMH for 422 non-pregnant patients, and 12-month AMH for 16 non-pregnant patients. POI was defined as FSH level>25 IU/L at month 12.

FSH and E2 values at month 12 were 9 IU/L (IQR: 7–14 IU/L) and 44 pg/ml (IQR: 23–77 pg/ml), respectively (Suppl Table 3). Of the 142 patients eligible for POI analysis, 15 (10.6 %) had POI. All 15 women with POI

had received prior chemotherapy (Table 1) and had low ovarian reserve, whereas 46.5 % of those without POI had low ovarian reserve (Suppl Table 4).

As expected, a higher proportion of POI was observed in older patients, with 2.5 % versus 15.9 % POI in patients aged below 35 years and between 40 and 42 years, respectively (Table 1). The duration of ET use was similar between POI and non-POI groups (Suppl Table 5). The proportion of POI was 15.4 % in patients who had prior ovarian function suppression (OFS) with/without aromatase inhibitors (OFS ± AI), 10.6 % of those who received selective estrogen receptor modulator (SERM) only, 8.7 % of those with other ET (Table 1).

The FSH values were available at both months 3 and 12 for 111 of 142 patients. The median 3-month FSH value was 31 IU/L (IQR: 6–45 IU/L) and 7 IU/L (IQR: 6–12 IU/L) in POI (n = 10) and non-POI patients (n = 101) (Suppl Table 6). The Spearman correlation coefficient for FSH values at months 3 and 12 was 0.37 (95 % CI: 0.19–0.52) (Suppl Fig. 1). An univariable logistic regression model showed a modest association between elevated FSH level at month 3 and the occurrence of POI (OR: 1.07; 95 % CI: 1.03 to 1.12).

AFC, an additional marker of ovarian reserve, was available in 57 of the 142 patients eligible for low ovarian reserve and POI analysis. As expected, AFC values were negatively associated with older age and prior chemotherapy. The median AFC was also lower in patients with low ovarian reserve vs patients without low ovarian reserve, and in patients with POI vs without POI (Suppl Table 7).

3.3. AMH and FSH as predictors of pregnancy

A total of 368 (74 %) of the 497 patients in the secondary analysis population reported at least one pregnancy during the study period [7]; while 72 % of patients in the low ovarian reserve analysis population reported at least one pregnancy (316/438). As previously reported [7], younger age and embryo transfer vs. no ART were positively associated with pregnancy, whereas prior chemotherapy and ET type and duration showed no association (Table 2). A multivariable logistic regression model showed that lower AMH values were associated with lower odds of pregnancy (Suppl Table 8). A similar model confirmed that the odds of pregnancy were lower by 48 % for patients with low ovarian reserve (OR: 0.52; 95 % CI: 0.31 to 0.87) (Table 2).

Table 2

Odds ratios for pregnancy (yes vs no) from multivariable logistic model including low ovarian reserve (AMH<0.5 ng/ml), among 438 patients in low ovarian reserve analysis population, of whom 316 became pregnant.

Odds Ratio Estimates			
Factor	Point Estimate	95 % Wald Confidence Limits*	
Low ovarian reserve: Yes vs No	0.523	0.314 0.873	
ART: Ovarian stimulation by IVF/ICSI on trial vs No ART	1.096	0.576 2.084	
ART: Embryo transfer vs No ART	2.518	1.220 5.195	
ART: Other ART vs No ART	1.355	0.716 2.567	
Age: <35 vs 40-42	4.641	2.444 8.812	
Age: 35-39 vs 40-42	2.708	1.605 4.569	
Prior chemotherapy: No vs Yes	0.717	0.423 1.216	
Prior ET: SERM only vs OFS±AI	1.066	0.553 2.054	
Prior ET: Other vs OFS±AI	1.170	0.608 2.251	
Duration prior ET (months)	0.958	0.906 1.013	

Note an interaction test (not provided) for the interaction between ART (Yes vs. No) and low ovarian reserve was not statistically significant (p-value: 0.170).

*Factors are considered associated with pregnancy if the 95 % Wald Confidence Limits do not include 1.000.

ART = Assisted Reproductive Technology; IVF/ICSI= In Vitro Fertilization/ Intracytoplasmic Sperm Injection; OFS= Ovarian Function Suppression, AI= Aromatase Inhibitors; SERM= Selective Estrogen Receptor Modulator; ET = Endocrine Therapy.

We observed similar pregnancy rates among women with low ovarian reserve, regardless whether ART was used (Table 3). Although different pregnancy rates were observed for patients with and without low ovarian reserve according to ART use (Table 3), this interaction was not statistically significant (p-value: 0.170). Among 209 patients with low ovarian reserve (AMH <0.5 ng/mL), 49 % utilized ART, compared to 43 % of patients with higher ovarian reserve (AMH ≥1.5 ng/mL); and 43 % of those in between (Suppl Table 9).

Finally, the multivariable logistic regression model, including 187 of 282 patients who did not use ART and had month 3 FSH levels, revealed a very modest association between FSH at month 3 and spontaneous pregnancy (OR: 0.96; 95 % CI 0.93–1.00.) (Suppl Tables 10–11).

3.4. Menstrual cycle characteristics

Among the 127 of 142 patients who did not have POI, 31.5 % (40/127) had experienced oligomenorrhea before month 12 (Suppl Table 12). The distributions of AMH and FSH levels at 3 and 12 months were similar regardless of their oligomenorrhea status during this period (Suppl Table 13).

Of 93 non pregnant patients at month 6 who had useable samples for progesterone and did not use ART, 60.2 % were ovulatory. Multivariable logistic regression showed that ovulatory status at month 6 was not predictive of subsequent spontaneous pregnancy (OR: 1.41; 95 % CI: 0.53–3.74) (Suppl Tables 14–15).

3.5. Prolactin and TSH

Prolactin (PRL) and TSH were evaluated at month 3 post-ET washout in 444 and 450 patients, respectively. Normal values were reported in most patients (Suppl Table 16). Separate multivariable logistic regression models did not show a negative association with pregnancy (Suppl Tables 17–18).

Table 3

Patient and treatment characteristics by use of ART, and pregnancy rates.

	ART ^a		No ART	
	Patients	Number (%) pregnant	Patients	Number (%) pregnant
Ovarian reserve analysis population (n = 438)	200	150 (75.0)	238	166 (69.7)
Low ovarian reserve (AMH<0.5 ng/ml) ^a				
Yes	102	67 (65.7)	107	70 (65.4)
No	98	83 (84.7)	131	96 (73.3)
Age at enrollment (years)				
<35	52	42 (80.8)	90	78 (86.7)
35-39	94	73 (77.7)	98	69 (70.4)
40-42	54	35 (64.8)	50	19 (38.0)
Prior chemotherapy				
No	70	53 (75.7)	95	61 (64.2)
Yes	130	97 (74.6)	143	105 (73.4)
Prior ET				
OFS±AI	33	26 (78.8)	39	26 (66.7)
SERM only	81	57 (70.4)	93	65 (69.9)
Other	86	67 (77.9)	106	75 (70.7)

ART = Assisted Reproductive Technology; IVF/ICSI= In Vitro Fertilization/ Intracytoplasmic Sperm Injection; OFS= Ovarian Function Suppression; AI= Aromatase Inhibitors; SERM= Selective estrogen receptor modulator; ET = Endocrine Therapy.

^a Although the difference in pregnancy success percentage between low ovarian reserve cohorts (no versus yes) was greater for patients who used ART (19.0 % higher for no low ovarian reserve) than for patients who did not use ART (7.9 % higher for no low ovarian reserve), the interaction test yielded p = 0.170. The covariates in the interaction model for pregnancy were: age, prior chemotherapy, prior ET, duration prior ET, low ovarian reserve (yes/no), and ART (yes/no).

4. Discussion

In this secondary endpoint analysis from the POSITIVE trial that assessed the hormone profiles at 3, 6 and 12 months after interrupting ET, we observed that around half of the eligible cohort experienced low ovarian reserve after the 3-month ET washout. As expected, low ovarian reserve was more frequent in older patients and patients who received prior chemotherapy; however, it was similar across type and duration of ET. Notably, low ovarian reserve was associated with lower odds of pregnancy. Surprisingly, only 10.6 % of patients who were not already pregnant at month 12 experienced POI, despite 63.4 % of them having received chemotherapy. Among those who received chemotherapy, 16.7 % experienced POI. Finally, FSH level at month 3 was associated with POI, but only modestly with pregnancy rates. Other parameters, such as ovulatory status, oligomenorrhea, PRL or TSH were not predictive of spontaneous pregnancy.

This study confirmed that older age and prior chemotherapy are associated with higher likelihood of low ovarian reserve, consistent with other studies [22–24]. The relatively modest incidence of low ovarian reserve in the POSITIVE cohort may be attributed to the young age of the POSITIVE population (cohort's median age was 37 years) [6] and variation in treatments. The impact of the type of chemotherapy regimen was not assessed in this study. Notably, nearly 40 % of patients did not receive chemotherapy, and among these, only 23 % had low ovarian reserve. While previous studies have reported a decrease in AMH levels in women using tamoxifen [22], its impact on fertility remains controversial [25]. Reassuringly, the type and duration of ET, including SERMs, were not associated with hormonal factors or fertility in the POSITIVE cohort.

The low POI rate is consistent with the previous POSITIVE analysis reporting a menstruation recovery rate of nearly 95 % within one year following ET interruption [7]. However, previous studies assessing treatment-related amenorrhea in premenopausal BC survivors showed lower rates of ovarian function recovery after treatment [26–29]. The low POI rate in the POSITIVE trial should be interpreted with caution. Not all patients received chemotherapy, and patients were younger than in most previous studies, being this a trial population who sought pregnancy. Moreover, POI was defined solely based on FSH values, without including oligomenorrhea in the definition [19]. Notably, not all patients with POI experienced oligomenorrhea within the first year, although it may be influenced by the use of ART, introducing a potential bias. Previous studies demonstrated that pregnancy is possible in young cancer survivors with POI, with a spontaneous conception rate of 4–10 % [30–32]. Finally, only patients who were not pregnant at month 12 (those likely facing more fertility issues) were included in the POI analysis. These findings suggest that POI is not the primary reason for not being pregnant at month 12 in the POSITIVE cohort.

We previously showed that 74 % of patients in the POSITIVE trial had at least one pregnancy, most being spontaneous [7]. Although younger age and embryo transfer were the primary factors associated with pregnancy, our current analysis demonstrated that low ovarian reserve was also associated with lower pregnancy rates. While AMH has been traditionally considered a poor predictor of pregnancy, data in cancer survivors remain limited [14]. In patients who receive ART, AMH is associated with lower response to ovarian stimulation and, consequently reduced pregnancy success [33]. However, among 215 patients who performed ART, only 18 underwent ovarian stimulation for IVF. A total of 68 patients underwent cryopreserved embryo transfer, and 17 received embryo/egg donation [7], for which pregnancy success does not depend upon AMH level. In fact, we did not find a significant interaction between ART and low ovarian reserve on pregnancy success. Moreover, the use of ART may be biased by the fact that all patients were actively trying to conceive as soon as possible and may have used their frozen material even when spontaneous conception might have been possible. Overall, these data suggest that attempt at spontaneous conception could also be recommended for patients with low ovarian

reserve before ART procedures in this population.

We also assessed FSH level at month 3 as a potential predictor of spontaneous pregnancy. In women with normal menstrual cycle, high FSH levels are considered a marker of sub-fertility in patients using ART, but its predictive value decreases for patients not using ART [34]. Although FSH levels at month 3 were slightly higher in patients who did not achieve pregnancy compared to those who did, median FSH values remained low (<10 IU/L) in both groups. This may explain why FSH at month 3 showed only a modest association with pregnancy outcomes.

While ovulation is necessary for unassisted conception, we did not find a correlation between ovulatory status at month 6 and the likelihood of subsequent spontaneous pregnancy. Ovarian function recovery often occurs within the first year after chemotherapy, but older age is more likely to be associated with lack of or late recovery [35]. Since ovulatory status was determined based on a single luteal progesterone level at month 6, some patients may have resumed ovulatory cycles after our assessment. However, we previously showed that only an additional 4 % of patients resumed menses between months 6 and 12 [7]. This confirms that anovulatory cycles at month 6, as well as oligomenorrhea, did not predict later spontaneous pregnancy in patients who interrupted ET. Likewise, thyroid disease and hyperprolactinemia are both factors associated with ovulatory dysfunction [36] and lower fertility. However, we found that abnormal TSH and PRL values were not associated with lower pregnancy rates. These results should be cautiously interpreted given wide confidence intervals and the small proportion of patients with abnormal TSH and PRL values.

Our findings should be considered in the context of certain limitations. First, time points analyses were limited to 3, 6 and 12 months after ET interruption. Moreover, we included samples collected >35 days without menstruation based on normal menses definition [37]. Patients with longer menstrual cycles may have had an inappropriately timed assessment. The ovulatory cycle may be underestimated in patients with irregular cycles due to reliance on a single progesterone measurement during presumed luteal phase at month 6 in non-pregnant women. This limitation may account for observed low ovulatory cycle rate. Other potential causes of infertility, including male factors, and ovarian reserve before treatment were not reported in the POSITIVE trial. Finally, the secondary endpoints analysis was performed on a relatively small number of eligible patients.

In conclusion, low ovarian reserve was observed in half of the population and was associated with lower pregnancy rates. Nevertheless, around 65 % of patients with low ovarian reserve achieved pregnancy, regardless of the use of ART. As expected, main factors associated with low ovarian reserve were age and chemotherapy, but not the type and duration of ET. Reassuringly, we reported a low incidence of POI in young BC patients who did not achieve pregnancy 12 months after ET interruption. These findings underscore the importance of providing comprehensive fertility counseling to young women who interrupt ET to pursue pregnancy, emphasizing the need for collaboration with reproductive healthcare specialists to optimize conception options. Such counseling ensures both cancer treatment and family planning can be most effectively integrated.

CRedit authorship contribution statement

Isabelle Demeestere: Writing – review & editing, Writing – original draft, Validation, Resources, Project administration, Investigation, Funding acquisition, Conceptualization. **Samuel M. Niman:** Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Formal analysis, Data curation. **Ann H. Partridge:** Writing – review & editing, Supervision, Resources, Funding acquisition, Conceptualization. **Daniela S. Diego:** Writing – review & editing, Writing – original draft. **Roswitha Kammler:** Writing – review & editing, Validation, Supervision, Project administration, Data curation. **Monica Ruggeri:** Writing – review & editing, Visualization, Supervision, Project administration, Funding acquisition, Conceptualization.

Marco Colleoni: Writing – review & editing, Resources. **Chikako Shimizu:** Writing – review & editing, Resources. **Cristina Saura:** Writing – review & editing, Resources. **Karen A. Gelmon:** Writing – review & editing, Resources. **Anna B. Saetersdal:** Writing – review & editing, Resources. **Judith R. Kroep:** Writing – review & editing, Resources. **Audrey Mailliez:** Writing – review & editing, Resources. **Frederic Amant:** Writing – review & editing, Resources. **Manuel Ruiz-Borrego:** Writing – review & editing, Resources. **Jeong Eon Lee:** Writing – review & editing, Resources. **Akemi Kataoka:** Writing – review & editing, Resources. **Janice M. Walshe:** Writing – review & editing, Resources. **Junko Takei:** Writing – review & editing, Resources. **Simona Borstnar:** Writing – review & editing, Resources. **Virginia F. Borges:** Writing – review & editing, Resources. **Christobel Saunders:** Writing – review & editing, Resources. **Snezana Susnjarić:** Writing – review & editing, Resources. **Vesna Bjelic-Radicic:** Writing – review & editing, Resources. **Fatima Cardoso:** Writing – review & editing, Resources. **Jane Lowe Meisel:** Writing – review & editing, Resources. **Jennifer F. Kawwass:** Writing – review & editing. **Tanja Spanic:** Writing – review & editing, Resources. **Sarra El-Abed:** Writing – review & editing, Resources. **Martine Piccart:** Writing – review & editing, Funding acquisition. **Larissa A. Korde:** Writing – review & editing, Conceptualization. **Aron Goldhirsch:** Writing – review & editing, Conceptualization. **Richard D. Gelber:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Funding acquisition, Formal analysis, Data curation, Conceptualization. **Olivia Pagani:** Writing – review & editing, Supervision, Resources, Funding acquisition, Conceptualization. **Hatem A. Azim:** Writing – review & editing, Supervision, Conceptualization. **Fedro A. Peccatori:** Writing – review & editing, Supervision, Resources, Conceptualization.

Prior presentation

An abstract of this work has been accepted for oral presentation at the 2025 ESMO Breast Cancer Annual Congress.

Ethical approval statement

The study was sponsored by the IBCSG in accordance with the International Council for Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki, and local clinical research regulations. The protocol was approved by the institutional review board at each participating center. All patients gave written informed consent.

Data sharing statement

After publication, access to de-identified participant data may be requested by researchers by submitting a proposal (to stat_center@ibcsg.org), which will be reviewed for scientific merit and feasibility in accordance with IBCSG guidelines for collaborative research and data sharing policy (<https://www.ibcsg.org/en/patients-professionals/research-collaboration>).

Funding

The Breast Cancer Research Foundation and Roche Diagnostics International provided financial support to IBCSG for translational research sample logistics and centralization, and Roche Diagnostics also provided reagents for serum testing at the central laboratory in Brussels. The Fonds de la Recherche Scientifique (FNRS-CRD) provided additional support for hormone analysis and biobanking at the central laboratory in Brussels. (Isabelle Demeestere is a Senior Researcher Associate at the FNRS).

The POSITIVE trial is supported by the ETOP IBCSG Partners Foundation (globally) and the Alliance for Clinical Trials in Oncology (in North America), in collaboration with the Breast International Group (BIG), the BIG cooperative groups, and the National Clinical Trials

Network of the National Cancer Institute.

Globally, the trial receives grant support for central or local trial conduct from the following: the International Breast Cancer Study Group (IBCSG), Frontier Science and Technology Research Foundation, Southern Europe (Frontier Southern Europe), Rising Tide Foundation for Clinical Cancer Research (CCR-15-120; CCR-20-200; CCR-24-150), Pink Ribbon Switzerland, Swiss Cancer League (KLS-3361-02), San Salvatore Foundation, Swiss Group for Clinical Cancer Research, Clinical Cancer Research Foundation of Eastern Switzerland, Ms. Elisabetta Pavesi, Verein Barguf, Swiss Cancer Foundation, Ms. Christine Hafner and Mr. Marc Wyss, Piajoh Fondazione di Famiglia, Gruppo Giovani Pazienti “Anna dai Capelli Corti”, and Schweizer Frauenlauf Bern — all in Switzerland; BIG Against Breast Cancer and the Baillet Latour Fund, Belgium; Gateway for Cancer Research (G-15-1900), United States; Fondazione Umberto Veronesi, Italy; C & A, Germany; Dutch Cancer Society, the Netherlands; Norwegian Breast Cancer Society and Pink Ribbon — both in Norway; ELGC K.K. and Pink Ring — both in Japan; Mr. Yong Seop Lee, Ms. Sun Hee Kang, and Korean Breast Cancer Foundation — all in South Korea; and other private donors.

In North America, the Alliance for Clinical Trials in Oncology receives support from the National Cancer Institute of the National Institutes of Health (NIH) (Alliance for Clinical Trials in Oncology National Cancer Institute Community Oncology Research Program [NCORP] grant UG1CA189823) and the biorepository resource grant U24CA196171; the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) receives support under grant UG1CA189828; SWOG Cancer Research Network receives support under NIH grants UG1CA189974 and U10CA180888; and NRG Oncology receives support under NIH grant U10CA180868 and NCORP grant UG1CA189867. Canadian Cancer Trials Group (CCTG) participation in the trial is supported through its grant from the National Cancer Institute of the NIH (CA180863). Funding support from the Dutch Cancer Society, The Netherlands (KaWeFis Batch7/7723). Additional programmatic funding support for the CCTG is provided by the Canadian Cancer Society (707213) and the Canada Foundation for Innovation. In addition, the trial receives support from RETHINK Breast Cancer, Canada, and the Gilson Family Foundation, United States.

Declaration of competing interest

I. Demeestere reported invited speaker honoraria from Ferring and support for attending congress from Theramex, Organon; Research Grant from ROCHE diagnosis, Ferring, Theramex (Inst.). **A.H.Partridge** reported Royalties for authorship of UpToDate: Wolters Kluwer; and non-Financial Interests as co-Chair of Breast Committee: Alliance for Clinical Trials, National Cancer Institute; and Chief Scientific Advisor: Susan G. Komen Foundation. **M.Colleoni:** reported Research Funding from Roche (Inst), and non-financial interest as Co-Chair of the International Breast Cancer Study Group Scientific Committee. **C. Shimizu** reported honoraria from AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Taiho Pharmaceutical, Pfizer, Daiichi Sankyo/UCB Japan, MSD; and research grant from Lilly. **C. Saura** reported Consulting or Advisory Role for AstraZeneca, Daiichi Sankyo, Eisai, MediTech, Novartis, Pfizer, Philips Healthcare, Pierre Fabre, Puma Biotechnology, Roche, SeaGen, Gilead Sciences, Pint Pharma, Synthon, Zymeworks, PharmaLex;

Speakers' Bureau for AstraZeneca, Daiichi Sankyo/Astra Zeneca, Pfizer, Pierre Fabre, Puma Biotechnology, Seagen, Exeter Pharmaceuticals, Lilly; Research Funding from Puma Biotechnology (Inst), Roche (Inst), AstraZeneca (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Bristol Myers Squibb (BMS) (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Roche (Inst), Genentech (Inst), GlaxoSmithKline (Inst), InnoUp (Inst), Lilly (Inst), MacroGenics (Inst), Menarini (Inst), Merus (Inst), Novartis (Inst), Pfizer (Inst), Sanofi/Aventis (Inst), Seagen (Inst); Travel, Accommodations, expenses from Pfizer, Novartis, Roche, AstraZeneca, Puma Biotechnology, Daiichi Sankyo, Eisai Europe and

other Relationship: Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd; **K.A. Gelmon** reported honoraria from AstraZeneca, Pfizer, Lilly, Novartis, Merck, Gilead, Seagen, City of Hope, Celcuity; AstraZeneca, Pfizer, BMS. **A.B. Saetersdal** reported Consulting or Advisory Role: Takeda Science Foundation. **Judith R. Kroep** reported the following institutional research grants from: KWF, AstraZeneca, Novartis, and Philips; receiving consulting fees from AstraZeneca, Daiichi, Eisai, GSK, Lilly, MSD, and Novartis; receiving support for attending meetings and/or travel from: Daiichi; participating on a data safety monitoring board or advisory board for: Alison and TEIPP trials; and serves in a leadership or fiduciary role (in other board, society, committee, or advocacy group, paid or unpaid) for EORTC-GCG. **A. Mailliez** reported honoraria as invited speaker or advisory role from AstraZeneca, MSD oncology, Novartis, Roche; Menarini, Oseus, Seagen, Pfizer, Daiichi Sankyo; and Expert Testimony for GSK. **F. Amant** reported honoraria from ROCHE and Advisory role for MiMARK Diagnostics; unrestricted research grant from Estée Lauder; **M. Ruiz-Borrego** reported Honoraria from Roche/Genentech, Pfizer, Novartis and Consulting or Advisory Role for Roche, Puma Biotechnology. **J.E.Lee**: reported receiving consulting fees from: MSD; receiving payment or honoraria (for lectures, presentations, speakers bureaus, manuscript writing or educational events) from: ExactScience and Takeda Korea; and serving in a leadership or fiduciary role (in other board, society, committee, or advocacy group, paid or unpaid) for: the Korean Breast Cancer Society.

Janice M. Walshe reported Honoraria from Novartis, Consulting or Advisory Role from Gilead Sciences; Travel, Accommodations, Expenses: Novartis. **Junko Takei** reported Speakers' Bureau role for AstraZeneca. **S. Borstnar** reported honoraria from AstraZeneca, Lilly, Pfizer, Novartis, Roche, MSD Oncology, Sandoz, Gilead Sciences, Consulting or Advisory Role: Novartis, AstraZeneca, Roche, Pfizer, MSD, Oncology, Lilly. **V. F. Borges** reported Stock and Other Ownership Interests: Perla Therapeutics, Consulting or Advisory Role for Seagen, AstraZeneca, Gilead Sciences, Research Funding: Seagen (Inst), Olema Oncology (Inst), AstraZeneca (Inst). **C Saunders**: reports serving in a leadership or fiduciary role (in other board, society, committee, or advocacy group, paid or unpaid) for PathWest Laboratory Medicine and Breast Cancer Trials. **S. Susnjar** reported Consulting or Advisory Role for AstraZeneca, Lilly, Novartis, Roche, Pfizer; Speakers' Bureau role for Amicus Therapeutics, Novartis, Pfizer, Research Funding: Roche (Inst); Travel, Accommodations, Expenses from Amicus Therapeutics, Roche.

V. Bjelic-Radasic reported consulting fees (to the institution) from: Pfizer, Roche, and Lilly; receiving payment or honoraria (to the institution, for lectures, presentations, speakers bureaus, manuscript writing or educational events) from: Pfizer and Lilly; receiving support for attending meetings and/or travel from: Pfizer; participating on a data safety monitoring board or advisory board for Pfizer; and serving in a leadership or fiduciary role (in other board, society, committee, or advocacy group, paid or unpaid) for AWOgyn.

F. Cardoso: reported consulting fees from: Amgen, Astellas/Medivation, AstraZeneca, Bayer, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung, Bioepis, Seagen, Teva, and Touchime; receiving payment or honoraria (for lectures, presentations, speakers bureaus, manuscript writing or educational events) from: Pfizer, Roche, Gilead, AstraZeneca, Novartis, and Merck; receiving support for attending meetings and/or travel from: Pfizer, Roche, Gilead, AstraZeneca, and Novartis; and serving in a leadership or fiduciary role (in other board, society, committee, or advocacy group, paid or unpaid) for ABC Global Alliance (President), ABC Consensus Conference and Guidelines (Chair), European Academy of Cancer Sciences (Fellow), and ESMO, ESO, ASCO, AACR, ECO, AORTIC, UICC, EORTC, IBCSG, SOLTI, EACR, SIS, ASPIC, SPO, and Evita (member/committee member).

T. Spanic: reported honoraria from Pfizer, MSD, Roche; Conseling and advisory role for Roche, Invited Speaker for Regional Meeting by AstraZeneca; Other, Podcast Guest: Novartis; Unrestricted Grant to Europa Donna Slovenija: Novartis, Roche, MSD, AstraZeneca, Lenis; and Non-Financial Interests as member of Board of Directors, Starting Jan 2025: ABC Global Alliance. **S. El-Abed**: reported the following institutional research grants from: AstraZeneca, Sanofi, Roche, Genentech, GlaxoSmithKline, Pfizer, and Novartis. **M. Piccart**: reported the following institutional research grants from: AstraZeneca, Lilly, Menarini, MSD, Novartis, Pfizer, Roche-Genentech, Servier, and Gilead; receiving consulting fees from: AstraZeneca, Gilead, Lilly, Menarini, Mersana, MSD, Novartis, Pfizer, Roche-Genentech, Seattle Genetics, Seagen, NBE Therapeutics, and Summit Therapeutics; receiving payment or honoraria (for lectures, presentations, speakers bureaus, manuscript writing or educational events) from: AstraZeneca, Gilead, Lilly, Menarini, Mersana, MSD, Novartis, Pfizer, Roche-Genentech, Seagen, NBE Therapeutics, and Summit Therapeutics; and participating on a data safety monitoring board or advisory board for Oncolytics. **R.D. Gelber**: reported research funding from AstraZeneca, Roche, Merck. **O. Pagani**: reported consulting or advisory role for Debiopharm. **H.A. Azim**: reported honoraria from Pierre Fabre, emergence therapeutics, Diaccurate, PEP Therapy, LinkinVax; Invited Speaker and travel accommodation expense from AstraZeneca, Novartis Stocks/Shares: Innate Pharma; Fatima Cardoso and Karen Gelmon are Editor-in-Chief and Deputy Editor in The Breast, respectively, and have no involvement in the peer-review of this article and no access to information regarding its peer review. Ann Partridge, Fedro Alessandro Peccatori and Hatem A Azim Jr are part of the Editorial Board of The Breast and were not involved in the editorial review or the decision to publish this article.

No other conflict of interest were reported.

Acknowledgements

The POSITIVE trial resulted from the collaboration of the Endocrine Working Group of the Breast International Group (BIG)-North American Breast Cancer Group (NABCG), and was collaboratively designed and conducted by the International Breast Cancer Study Group (IBCSG; the sponsor and coordinating group), and cooperative groups affiliated with BIG, and the Alliance for Clinical Trials in Oncology (the sponsor in North America), including the National Clinical Trials Network of the National Cancer Institute and others.

We sincerely thank the patients and their families, the above-mentioned trial partners, the supporters (all national funding bodies, charities, and private donors), the collaborators, the current and former members of the trial's Committees and the Investigators.

We thank Julie Dechène and Miriam Christoffel for their invaluable assistance with blood sample logistics and centralization.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.breast.2025.104547>.

References

- [1] Ellington TD, Miller JW, Henley SJ, Wilson RJ, Wu M, Richardson LC. Trends in breast cancer incidence, by race, ethnicity, and age among women aged ≥ 20 years - united States, 1999-2018. *MMWR Morb Mortal Wkly Rep* 2022;71(2):43-7. <https://doi.org/10.15585/mmwr.mm7102a2>.
- [2] Cancer facts and figures 2018 - estimated number of new cases for the four major cancers by sex and age group. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/estimated-number-of-new-cases-for-the-four-major-cancers-by-sex-and-age-group-2018.pdf>.
- [3] Practice Committee of the American Society for Reproductive Medicine. Electronic address aao: fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. *Fertil Steril* 2019;112(6):1022-33. <https://doi.org/10.1016/j.fertnstert.2019.09.013>.

- [4] American College of O, Gynecologists Committee on Gynecologic P, Practice C. Female age-related fertility decline. Committee opinion no. 589. *Fertil Steril* 2014; 101(3):633–4. <https://doi.org/10.1016/j.fertnstert.2013.12.032>.
- [5] National Comprehensive Cancer Network. *Breast Cancer*. [https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf].
- [6] Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim Jr HA, Colleoni M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. *N Engl J Med* 2023;388(18):1645–56. <https://doi.org/10.1056/NEJMoa2212856>.
- [7] Azim Jr HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, et al. Fertility preservation and assisted reproduction in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy. *J Clin Oncol* 2024; 2822–32. <https://doi.org/10.1200/JCO.23.02292>.
- [8] Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice Guidelines(dagger). *Ann Oncol* 2020;31(12): 1664–78. <https://doi.org/10.1016/j.annonc.2020.09.006>.
- [9] European Society for Human R, Embryology Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J. ESHRE guideline: management of women with premature ovarian insufficiency. *Hum Reprod* 2016;31(5):926–37. <https://doi.org/10.1093/humrep/dew027>.
- [10] Anderson RA, Amant F, Braat D, D'Angelo A, Chuva de Sousa Lopes SM, Demeestere I, et al. ESHRE guideline: female fertility preservation. *Hum Reprod Open* 2020;2020(4):hoaa052. <https://doi.org/10.1093/hropen/hoaa052>.
- [11] La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Arsenio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). *Hum Reprod Update* 2010;16(2):113–30. <https://doi.org/10.1093/humupd/dmp036>.
- [12] Poseidon G, Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. *Fertil Steril* 2016;105(6): 1452–3. <https://doi.org/10.1016/j.fertnstert.2016.02.005>.
- [13] Peigne M, Bernard V, Dijols L, Creux H, Robin G, Hocke C, et al. Using serum Anti-Mullerian hormone levels to predict the chance of live birth after spontaneous or assisted conception: a systematic review and meta-analysis. *Hum Reprod* 2023;38(9):1789–806. <https://doi.org/10.1093/humrep/dead147>.
- [14] Anderson RA, Cameron D, Clatot F, Demeestere I, Lambertini M, Nelson SM, et al. Anti-Mullerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. *Hum Reprod Update* 2022;28(3):417–34. <https://doi.org/10.1093/humupd/dmac004>.
- [15] Bala J, Seth S, Dhankhar R, Ghalaut VS. Chemotherapy: impact on anti-mullerian hormone levels in breast carcinoma. *J Clin Diagn Res* 2016;10(2):BC19–21. <https://doi.org/10.7860/JCDR/2016/15933.7328>.
- [16] Dezellus G, Barriere P, Campono M, Lemanski C, Vanlemmens L, Mignot L, et al. Prospective evaluation of serum Anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. *Eur J Cancer* 2017;79:72–80. <https://doi.org/10.1016/j.ejca.2017.03.035>.
- [17] Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. *Ann Oncol* 2020. <https://doi.org/10.1016/j.annonc.2020.09.006>.
- [18] Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim Jr HA, Colleoni M, et al. Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. *Breast* 2021;59:327–38. <https://doi.org/10.1016/j.breast.2021.07.021>.
- [19] Eshre AC, Imsggo POI, Panay N, Anderson RA, Bennie A, Cedars M, et al. Evidence-based guideline: premature ovarian insufficiency. *Fertil Steril* 2025;123(2): 221–36. <https://doi.org/10.1016/j.fertnstert.2024.11.007>.
- [20] Practice committees of the American society for reproductive M, the society for reproductive E, infertility: diagnosis and treatment of luteal phase deficiency: a committee opinion. *Fertil Steril* 2021;115(6):1416–23. <https://doi.org/10.1016/j.fertnstert.2021.02.010>.
- [21] Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of Anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. *Hum Reprod* 2007;22(7):1837–40.
- [22] Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. *Fertil Steril* 2010;94(2):638–44.
- [23] Peccatori FA, Azim Jr HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013;24(Suppl 6):vi160–70. <https://doi.org/10.1093/annonc/mdl199>.
- [24] Mailliez A, Pigny P, Bogart E, Keller L, D'Orazio E, Vanseymortier M, et al. Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients. *Int J Cancer* 2022;150(11):1850–60. <https://doi.org/10.1002/ijc.33933>.
- [25] Shandley LM, Spencer JB, Fothergill A, Mertens AC, Manatunga A, Paplomata E, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. *Fertil Steril* 2017;107(1):243–252 e245. <https://doi.org/10.1016/j.fertnstert.2016.10.020>.
- [26] Jacobson MH, Mertens AC, Spencer JB, Manatunga AK, Howards PP. Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. *Fertil Steril* 2016;105(3):765–772 e764. <https://doi.org/10.1016/j.fertnstert.2015.11.020>.
- [27] Poorvu PD, Hu J, Zheng Y, Gelber SI, Ruddy KJ, Tamimi RM, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. *NPJ Breast Cancer* 2021;7(1):99. <https://doi.org/10.1038/s41523-021-00307-8>.
- [28] Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, et al. Adjuvant Anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-Positive early breast cancer patients. *J Natl Cancer Inst* 2018. <https://doi.org/10.1093/jnci/djy094>.
- [29] Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Juckstock J, et al. Anti-Mullerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - a translational research project of the SUCCESS A study. *Breast* 2017;35:130–5. <https://doi.org/10.1016/j.breast.2017.07.007>.
- [30] Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. *J Clin Oncol* 2016;34(22): 2568–74. <https://doi.org/10.1200/JCO.2015.65.8864>.
- [31] Chabut M, Schneider P, Courbiere B, Saultier P, Bertrand Y, Tabone MD, et al. Ovarian function and spontaneous pregnancy after hematopoietic stem cell transplantation for leukemia before puberty: an L.E.A. cohort study. *Transplant Cell Ther* 2023;29(6):378 e371–9. <https://doi.org/10.1016/j.jctc.2023.02.019>.
- [32] Podfigurna-Stopa A, Czyzyk A, Grymowicz M, Smolarczyk R, Katulski K, Czajkowski K, et al. Premature ovarian insufficiency: the context of long-term effects. *J Endocrinol Investig* 2016;39(9):983–90. <https://doi.org/10.1007/s40618-016-0467-z>.
- [33] Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. *Hum Reprod Open* 2020;2020(2):1–13. <https://doi.org/10.1093/hropen/hoaa009>.
- [34] van Montfrans JM, Hoek A, van Hooff MH, de Koning CH, Tonch N, Lambalk CB. Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population. *Fertil Steril* 2000;74(1):97–103. [https://doi.org/10.1016/s0015-0282\(00\)00560-4](https://doi.org/10.1016/s0015-0282(00)00560-4).
- [35] Kabirian R, Franzoi MA, Havas J, Coutant C, Tredan O, Levy C, et al. Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer. *JAMA Netw Open* 2023;6(11):e2343910. <https://doi.org/10.1001/jamanetworkopen.2023.43910>.
- [36] Practice Committee of the American Society for Reproductive Medicine. Electronic address aao: current evaluation of amenorrhea: a committee opinion. *Fertil Steril* 2024;122(1):52–61. <https://doi.org/10.1016/j.fertnstert.2024.02.001>.
- [37] Committee on Practice B-G. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. *Obstet Gynecol* 2012;120(1): 197–206. <https://doi.org/10.1097/AOG.0b013e318262e320>.